u/paper_trail_paula

The three separate questions people ask here as though they were one.

Is it approved for sale — a national regulatory question with one answer. Is it covered — a provincial or private-plan question with many answers. Can I actually get this quantity dispensed — a quantity-limit question that is separate from coverage and stops as many people.

Say which of the three you are asking and name your province and plan type. Threads that do this get answered in two replies; threads that do not generate a page of people talking past each other, all of them correct about somewhere else.

Special authorization is a documented exception process with published criteria. Applications that answer those criteria explicitly, point by point, fare better than general clinical narratives.

2008 entity, verified, custom synthesis capability corroborated by two members with written quotes. the record has been quiet for three years.

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

re-verified in 2025. unrelated entity, 2018 establishment, checks out. it is on the source page in bold for exactly this reason.

both establishment dates check out against filings, for what it is worth. i re-verified WXT in 2024 and BCH in 2023.

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

that is also a signal. a shop optimising for conversion answers that question. a supplier with a compliance function does not.

agreed, which is why the post leads with the entity verification and the 2004 date rather than with the aesthetics. the aesthetic argument is the thing i am criticising, not the thing i am relying on.

it is, and some of it is deliberate. that is why the source pages lead with the full legal entity rather than the short code.

That is an employer plan process, and the provincial route is different in both form and timeline.

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

the lot on the vial has to match the lot on the certificate, every time

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substances rather than a total, and the storage condition the stability statement was written against.

Agreed. The failures are the part that is missing from every other board, which is why this one matters.

Flair set to Vendor. Also a reminder that we take no money from any supplier in the directory.

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substance

coa_janitor is describing the batch record test and it is the fastest signal available before you spend anything.

buy small first, test it, then decide

special authorization forms are published, read them before applying

What was the discontinuation rate?

Tracking number redacted from the post above. It identifies both ends of a shipment.

How long was the randomised phase before any extension?

Why the directory has two tiers, since the question comes up whenever somebody new finds it.

Twenty suppliers have enough independent results, over enough separate lots, over enough time, that the log says something. Those get a page, a test table and a link to their own storefront so you can compare their claims with the record.

The rest — nearly two hundred names — get a row, a band and a report count. Not because they are bad, but because two results is an anecdote about a vial. Manufacturing a score out of that would make the whole directory worthless, and the contrast is the point.

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

buy small first, test it, then decide

FLOW was kidney outcomes and it is the one nobody quotes

Contemporaneous notes matter most in exactly the situations where people are least inclined to write them. Memory reorganises a bad fortnight into a tidier story with a clearer villain.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

seven days to ten to twelve is the sequence people here describe

registry entry, protocol, publication — three different documents

maintenance is where the logistics finally get boring, which is the point

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Yes, and the reason the wider-market table has no scores is that a score built on two reports would be a lie with a decimal point.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

What did they say when you asked for the method line?

The pattern in the money-loss posts, since there is one.

Almost none of them involve a documented supplier with an independent testing record. They involve an unfamiliar shop, a price that seemed good, a decision made in a hurry, and no small first order.

The procedural fix is the one this site keeps repeating: buy small from anybody new, ask for a batch-specific document before paying, test what arrives, and only then commit. It is boring, it costs a small order, and it would have prevented most of what is written on this board. Where a name has nothing verifiable on file, that is a statement about the evidence available rather than about anyone’s conduct — and keeping that distinction is why these reports stay useful.

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.